Drug intelligence / Profile preview

methotrexate + vindesine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

This drug is a combination chemotherapy regimen consisting of methotrexate and vindesine. Methotrexate is a folate analog antimetabolite that inhibits dihydrofolate reductase, leading to inhibition of nucleotide synthesis and suppression of cell division, used in various cancers and inflammatory diseases. Vindesine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation which arrests mitosis at metaphase, leading to cancer cell death. The combination leverages different mechanisms targeting cancer cells at multiple points in the cell cycle for enhanced antitumor efficacy.

Other names: methotrexate + vindesine

Targets

DHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on methotrexate + vindesine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + vindesine.

Explore the full profile